CATAPRES TAB 0.2MG TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CLONIDINE HYDROCHLORIDE

Dostopno od:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Koda artikla:

C02AC01

INN (mednarodno ime):

CLONIDINE

Odmerek:

0.2MG

Farmacevtska oblika:

TABLET

Sestava:

CLONIDINE HYDROCHLORIDE 0.2MG

Pot uporabe:

ORAL

Enote v paketu:

100

Tip zastaranja:

Prescription

Terapevtsko območje:

CENTRAL ALPHA-AGONISTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0108891002; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2015-03-30

Lastnosti izdelka

_Catapres_
_®_
_ Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
PR
CATAPRES
®
(Clonidine Hydrochloride)
Boehringer Ingelheim Standard
TABLETS
0.1
mg, 0.2 mg
Antihypertensive
Boehringer Ingelheim (Canada) Ltd
5180 South Service Road
Burlington, Ontario
L7L 5H4
Date of Revision:
June 21, 2012
SUBMISSION CONTROL NO: 154435
Catapres
®
is a registered trademark used under license by Boehringer Ingelheim
(Canada) Ltd.
CCDS 0067-03
_ _
_Catapres_
_®_
_ Product Monograph _
_Page 2 of 29 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
..........................................................................16
DET